7633-68-3 Usage
Description
Isotalatizidine is an aconitine alkaloid that has been isolated from Aconitum talassicum and Delphinium denudatum, providing a connection between the chemical bases of these two plant genera. It forms a crystalline monohydrate from moist solvents, with a melting point of 116-117°C. The methiodide derivative has a melting point of 200°C, and the oxalate derivative has a melting point of 185-186°C. Isotalatizidine contains three hydroxyl groups that can be acetylated, with the 10-acetate being identical to Condelphine.
Uses
1. Used in Pharmaceutical Industry:
Isotalatizidine is used as a pharmaceutical compound for its potential therapeutic applications. The presence of hydroxyl groups allows for chemical modifications, which can enhance its bioactivity and pharmacological properties.
2. Used in Chemical Research:
Isotalatizidine serves as a valuable compound in chemical research, particularly in the study of aconitine alkaloids and their derivatives. Its structural features and the ability to form various derivatives make it an interesting subject for further investigation and potential drug development.
3. Used in Natural Product Chemistry:
Isotalatizidine is used as a representative example of the diverse range of alkaloids found in nature, particularly in plants from the Aconitum and Delphinium genera. Its study contributes to the understanding of the chemical diversity and biological activities of natural products.
4. Used in Toxicological Studies:
Due to the potential toxic effects of aconitine alkaloids, isotalatizidine can be used in toxicological studies to better understand the mechanisms of action and develop strategies for mitigating their toxic effects.
5. Used in Drug Development:
Isotalatizidine may be used as a starting point for the development of new drugs, particularly in the areas of pain management and treatment of certain conditions, given its alkaloid nature and potential pharmacological properties. Further research and development are necessary to explore its full potential in this application.
References
Rabinovitch, Konovalova., Bull. Soc. Chirn. Fr., 7,95 (1940)Kuzovkov, Platonova., J. Gen. Chern., USSR, 1286 (1961)Pelletier, Keith, Parthsarathy., Tetrahedron Lett., 4217 (1966)Pelletier, Keith, Parthsarathy., J. Arner. Chern. Soc., 89,4146 (1967)
Check Digit Verification of cas no
The CAS Registry Mumber 7633-68-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,6,3 and 3 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 7633-68:
(6*7)+(5*6)+(4*3)+(3*3)+(2*6)+(1*8)=113
113 % 10 = 3
So 7633-68-3 is a valid CAS Registry Number.
7633-68-3Relevant articles and documents
Total synthesis, relay synthesis, and structural confirmation of the C18-norditerpenoid alkaloid neofinaconitine
Shi, Yuan,Wilmot, Jeremy T.,Nordstrom, Lars Ulrik,Tan, Derek S.,Gin, David Y.
supporting information, p. 14313 - 14320 (2013/10/21)
The first total synthesis of the C18-norditerpenoid aconitine alkaloid neofinaconitine and relay syntheses of neofinaconitine and 9-deoxylappaconitine from condelphine are reported. A modular, convergent synthetic approach involves initial Diels-Alder cycloaddition between two unstable components, cyclopropene 10 and cyclopentadiene 11. A second Diels-Alder reaction features the first use of an azepinone dienophile (8), with high diastereofacial selectivity achieved via rational design of siloxydiene component 36 with a sterically demanding bromine substituent. Subsequent Mannich-type N-acyliminium and radical cyclizations provide complete hexacyclic skeleton 33 of the aconitine alkaloids. Key endgame transformations include the installation of the C8-hydroxyl group via conjugate addition of water to a putative strained bridghead enone intermediate 45 and one-carbon oxidative truncation of the C4 side chain to afford racemic neofinaconitine. Complete structural confirmation was provided by a concise relay synthesis of (+)-neofinaconitine and (+)-9-deoxylappaconitine from condelphine, with X-ray crystallographic analysis of the former clarifying the NMR spectral discrepancy between neofinaconitine and delphicrispuline, which were previously assigned identical structures.
